- Latest available (Revised)
- Original (As made)
There are currently no known outstanding effects for the The Human Medicines (Amendment etc.) (EU Exit) Regulations 2019, Section 4.
Revised legislation carried on this site may not be fully up to date. At the current time any known changes or effects made by subsequent legislation have been applied to the text of the legislation you are viewing by the editorial team. Please see ‘Frequently Asked Questions’ for details regarding the timescales for which new effects are identified and recorded on this site.
4. After regulation 2, insert—
2A.—(1) In these Regulations, [F1in their application to products for sale or supply in Great Britain only,] “advanced therapy medicinal product” means any of the following products—
(a)a gene therapy medicinal product;
(b)a somatic cell therapy medicinal product; or
(c)a tissue engineered product.
(2) A “gene therapy medicinal product” is a biological medicinal product which has the following characteristics—
(a)it contains an active substance which contains or consists of a recombinant nucleic acid used in or administered to human beings with a view to regulating, repairing, replacing, adding or deleting a genetic sequence; and
(b)its therapeutic, prophylactic or diagnostic effect relates directly to the recombinant nucleic acid sequence it contains, or to the product of genetic expression of this sequence.
(3) A vaccine against infectious diseases is not to be treated as a gene therapy medicinal product.
(4) A “somatic cell medicinal product” is a medicinal product which has the following characteristics—
(a)it contains or consists of cells or tissues that—
(i)have been subject to substantial manipulation so that biological characteristics, physiological functions or structural properties relevant for the intended clinical use have been altered, or
(ii)are not intended to be used for the same essential function in the recipient as in the donor; and
(b)it is presented as having properties for, or is used in or administered to human beings with a view to, treating, preventing or diagnosing a disease through the pharmacological, immunological or metabolic action of its cells or tissues.
(5) A “tissue engineered product” is a medicinal product which—
(a)contains or consists of engineered cells or tissues; and
(b)is presented as having properties for, or is used in or administered to human beings with a view to, regenerating, repairing or replacing a human tissue.
(6) A tissue engineered product may contain—
(a)cells or tissues of human or animal origin;
(b)viable or non-viable cells or tissues; and
(c)additional substances, including cellular products, bio-molecules, biomaterials, chemical substances, scaffolds or matrices.
(7) A product is not a tissue engineered product if it—
(a)contains or consists exclusively of non-viable human or animal cells or tissues;
(b)does not contain any viable cells or tissues; and
(c)does not act principally by pharmacological, immunological or metabolic action.
(8) Cells or tissues are engineered if they—
(a)have been subject to substantial manipulation, so that biological characteristics, physiological functions or structural properties relevant for the intended regeneration, repair or replacement are achieved; or
(b)are not intended to be used for the same essential function in the recipient as in the donor.
(9) The following manipulations are not substantial manipulations for the purposes of paragraphs (4)(a) and (8)(a)—
(a)cutting;
(b)grinding;
(c)shaping;
(d)centrifugation;
(e)soaking in antibiotic or antimicrobial solutions;
(f)sterilisation;
(g)irradiation;
(h)cell separation, concentration or purification;
(i)filtering;
(j)lyophilisation;
(k)freezing;
(l)cryopreservation; and
(m)vitrification.
(10) In these Regulations, [F1in their application to products for sale or supply in Great Britain only,] “combined advanced therapy medicinal product” means an advanced therapy medicinal product—
(a)which incorporates, as an integral part of the product, one or more medical devices or one or more active implantable medical devices; and
(b)the cellular part of which—
(i)contains viable cells or tissues; or
(ii)contains non-viable cells or tissues which are liable to act upon the human body with action that can be considered as primary to that of the medical devices.
(11) Where an advanced therapy medicinal product contains viable cells or tissues, the pharmacological, immunological or metabolic action of those cells or tissues is to be treated as the principal mode of action of the product.
(12) An advanced therapy medicinal product containing both autologous and allogeneic cells or tissues is to be treated as being for allogeneic use.
(13) A product which falls within the definition of a tissue engineered product and within the definition of a somatic cell therapy medicinal product is to be treated as a tissue engineered product.
(14) A product which falls within the definition of—
(a)a somatic cell therapy medicinal product or a tissue engineered product; and
(b)a gene therapy medicinal product,
is to be treated as a gene therapy medicinal product.”.
Textual Amendments
F1Words in reg. 4 inserted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 1
Commencement Information
I1Reg. 4 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1
The Whole Instrument you have selected contains over 200 provisions and might take some time to download. You may also experience some issues with your browser, such as an alert box that a script is taking a long time to run.
Would you like to continue?
The Whole Instrument you have selected contains over 200 provisions and might take some time to download.
Would you like to continue?
The Whole Instrument without Schedules you have selected contains over 200 provisions and might take some time to download. You may also experience some issues with your browser, such as an alert box that a script is taking a long time to run.
Would you like to continue?
The Whole Instrument without Schedules you have selected contains over 200 provisions and might take some time to download.
Would you like to continue?
The Whole Instrument you have selected contains over 200 provisions and might take some time to download. You may also experience some issues with your browser, such as an alert box that a script is taking a long time to run.
Would you like to continue?
The Whole Instrument without Schedules you have selected contains over 200 provisions and might take some time to download. You may also experience some issues with your browser, such as an alert box that a script is taking a long time to run.
Would you like to continue?
The Schedules you have selected contains over 200 provisions and might take some time to download. You may also experience some issues with your browser, such as an alert box that a script is taking a long time to run.
Would you like to continue?
Latest Available (revised):The latest available updated version of the legislation incorporating changes made by subsequent legislation and applied by our editorial team. Changes we have not yet applied to the text, can be found in the ‘Changes to Legislation’ area.
Original (As Enacted or Made): The original version of the legislation as it stood when it was enacted or made. No changes have been applied to the text.
Geographical Extent: Indicates the geographical area that this provision applies to. For further information see ‘Frequently Asked Questions’.
Show Timeline of Changes: See how this legislation has or could change over time. Turning this feature on will show extra navigation options to go to these specific points in time. Return to the latest available version by using the controls above in the What Version box.
Explanatory Memorandum sets out a brief statement of the purpose of a Statutory Instrument and provides information about its policy objective and policy implications. They aim to make the Statutory Instrument accessible to readers who are not legally qualified and accompany any Statutory Instrument or Draft Statutory Instrument laid before Parliament from June 2004 onwards.
Access essential accompanying documents and information for this legislation item from this tab. Dependent on the legislation item being viewed this may include:
Impact Assessments generally accompany all UK Government interventions of a regulatory nature that affect the private sector, civil society organisations and public services. They apply regardless of whether the regulation originates from a domestic or international source and can accompany primary (Acts etc) and secondary legislation (SIs). An Impact Assessment allows those with an interest in the policy area to understand:
This timeline shows the different points in time where a change occurred. The dates will coincide with the earliest date on which the change (e.g an insertion, a repeal or a substitution) that was applied came into force. The first date in the timeline will usually be the earliest date when the provision came into force. In some cases the first date is 01/02/1991 (or for Northern Ireland legislation 01/01/2006). This date is our basedate. No versions before this date are available. For further information see the Editorial Practice Guide and Glossary under Help.
Use this menu to access essential accompanying documents and information for this legislation item. Dependent on the legislation item being viewed this may include:
Click 'View More' or select 'More Resources' tab for additional information including: